Li Jingdong, Xiong Yongfu, Yang Gang, Zhang Lixing, Riaz Muhammad, Xu Jian, Li Qiang, Tang Zhaohui
Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
Institute of Hepato-Biliary-Pancreatic-Intestinal Disease, North Sichuan Medical College, Nanchong, China.
Wideochir Inne Tech Maloinwazyjne. 2021 Mar;16(1):62-75. doi: 10.5114/wiitm.2020.97363. Epub 2020 Jul 16.
The landscape of surgical treatments for hepatobiliary disease was significantly changed after the advent of laparoscopy. Many kinds of complex laparoscopic procedures can be routinely performed at present, but radical resection of hilar cholangiocarcinoma (HC) by laparoscopy is still highly contentious.
To describe our primary experience with laparoscopic radical resection for HC and determine the safety and feasibility of this procedure.
Between December 2015 and November 2019, 32 patients planned to undergo curative-intent laparoscopic resection of HC in our department. The perioperative and long-term outcomes of these patients were retrospectively analyzed.
Laparoscopic surgery with radical resection was ultimately performed in 24 (75.0%) patients; 3 (9.3%) patients were found to be unresectable at the preliminary exploration stage, and 5 (15.7%) patients converted from laparoscopy to laparotomy. The operation time and blood loss were 476.95 ±133.89 min and 568.75 ±324.01 ml, respectively. A negative margin was achieved in 19 (79.1%) of the laparoscopy patients. Three (12.5%) patients were identified with microscopic positive margins, and 2 (8.4%) patients underwent macroscopic residual tumor resection (R2). The length of postoperative stay was 23.3 ±11.7 days. Severe morbidity occurred in 4 (16.6%) patients. The actuarial 3-year overall survival and disease-free survival for patients who underwent laparoscopic surgery were 49.1% and 47.0%, respectively.
Laparoscopic radical resection for HC is safe and feasible in experienced hands for highly selected patients but is still in its initial stages. When adequate oncologic resection is performed, the laparoscopic approach does not adversely influence the prognosis of the patient.
腹腔镜技术出现后,肝胆疾病的外科治疗格局发生了显著变化。目前许多复杂的腹腔镜手术都可常规开展,但腹腔镜下肝门胆管癌(HC)根治性切除术仍极具争议。
描述我们开展腹腔镜下HC根治性切除术的初步经验,并确定该手术的安全性和可行性。
2015年12月至2019年11月,我科有32例计划接受HC根治性腹腔镜切除术的患者。对这些患者的围手术期和长期结局进行回顾性分析。
最终24例(75.0%)患者接受了腹腔镜根治性手术;3例(9.3%)患者在初步探查阶段被发现无法切除,5例(15.7%)患者由腹腔镜手术转为开腹手术。手术时间和出血量分别为476.95±133.89分钟和568.75±324.01毫升。19例(79.1%)腹腔镜手术患者切缘阴性。3例(12.5%)患者病理切缘微阳性,2例(8.4%)患者接受了肉眼残留肿瘤切除术(R2)。术后住院时间为23.3±11.7天。4例(16.6%)患者发生严重并发症。接受腹腔镜手术患者的3年总生存率和无病生存率分别为49.1%和47.0%。
对于经过严格筛选的患者,由经验丰富的术者操作,腹腔镜下HC根治性切除术是安全可行的,但仍处于初始阶段。当进行充分的肿瘤切除时,腹腔镜手术方法不会对患者预后产生不利影响。